Abstract: An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (?) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 23 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.

Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

Abstract: The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.

Abstract: The present invention concerns lectins isolated from the fruiting body of a novel Hericium erinaceum (deposit number: KCTC 12499BP) NEU-1L strain which bind specifically to sialic acid. The invention further pertains to uses of such lectinsn abd to processes for their preparation thereby. The lectin of the present invention can be useful as an active ingredient of a composition or a kit for measuring or detecting glycoproteins, glycopeptides, glycolipids, sugar precursors or oligosaccharides containing sialic acid moieties, or further for measuring or detecting cell lines, bacteria and viruses containing sialoglycoconjugates.

Abstract: EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.

Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2RP receptor and a decreased binding capacity for IL-2R?c receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

Abstract: The present invention relates a method of preparing a Glucagon-like peptide 2 (GLP-2) analog by gene recombination. The present invention provides an expression vector, which includes: (a) a nucleic acid sequence encoding tag protein; (b) a nucleic acid sequence encoding Smt3 protein (SEQ ID NO: 1); and (c) a nucleic acid sequence encoding linker peptide (SEQ ID NO: 2) and GLP-2 analog. The fusion protein expressed by the expression vector can be cleaved by thrombin, wherein the cleaving position is at the linker peptide, and then the GLP-2 analog is produced.

Abstract: Somatostatin derivative compounds of general formula (I) that may be readily labelled with the isotope fluorine-18 and that have affinity and selectivity for cellular somatostatin receptors are provided. The labelled compounds are useful clinically as radioactive tracers in various in vivo imaging applications (for example, using positron emission tomography (PET) and related techniques) to detect somatostatin-expressing cells and tissues, including tumors, or as therapeutic agents.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.

Abstract: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.

Abstract: The present inventors successfully provided constant regions capable of enhancing the agonist activity of antibodies through amino acid sequence alterations. Specifically, agonist activity was found to be enhanced in antibodies having a constant region in which amino acids of the antibody heavy chain constant region are substituted or deleted, or antibodies having a constant region in which the hinge region amino acids are substituted. Use of such antibodies as pharmaceutical formulations can provide pharmaceutical formulations with improved performance.

Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.

Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.

Abstract: The present invention relates to CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions.

Abstract: The disclosure provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.

Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.

Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.

Abstract: The present disclosure relates to in vivo methods for producing anti-idiotypic antibodies. In some aspects, anti-idiotypic antibodies are generated by co-administering to a mouse a first antibody having a murine IgG2a isotype and a second antibody that targets mouse B cells and has a murine IgG2a isotype. In some embodiments, the mouse expresses the Igh-1b allele of IgG2a, and the second antibody binds a mouse B cell surface marker selected from the group consisting of CD19, CD20, CD21, CD22, CD40, CD45, IgM, and IgD.

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

Abstract: An aqueous dispersion of fructan-containing particles, wherein the D50 of the fructan-containing particles lies between 2 ?m and 50 ?m and the solids content of the aqueous dispersion lies between 61 wt. % and 80 wt. %. Also described is a process for the preparation of an aqueous dispersion of fructan-containing particles comprising: bringing fructan and water together to form a mixture; optionally hydrolyzing a portion of the fructans in the mixture, such that at the end of this step between 5 wt. % and 25 wt. % of all fructans in the mixture are essentially non-soluble at room temperature; optionally bring the mixture into contact with a purification agent, followed by removal of the purification agent from the mixture; and concentrating the mixture such that the solids content lies between 61 and 80%.

Abstract: The present invention aims to provide a production method that can produce an aqueous dispersion containing polyvinylidene fluoride with high productivity. The present invention relates to a method of producing an aqueous dispersion of polyvinylidene fluoride, including: emulsion polymerization of vinylidene fluoride in the presence of a surfactant, an organic peroxide, and water to produce an aqueous dispersion that contains polyvinylidene fluoride. The surfactant has a surface tension of 55 mN/m or smaller when added in an amount of 1000 ppm.

Abstract: Heterocyclic amido transition metal complexes are disclosed for use in alkene polymerization to produce polyolefins, preferably multimodal polyolefins. The heterocyclic amido transition metal complexes are formed by the chelation of a tridentate dianionic heterocyclic amido ligand to a group 3, 4, or 5 transition metal, where the tridentate ligand coordinates to the metal forming a five-membered ring and an eight-membered ring.

Abstract: A catalyst component (A) for olefin polymerization is prepared by contacting a solid component (a) containing magnesium, titanium, halogen and an internal electron donor compound with an organosilicon compound (b), wherein the organosilicon compound (b) is one or more selected from a Si—H functional group containing chainlike polysiloxane (b1) represented by formula (Ix), a cyclic polysiloxane (b2) represented by formula (Iy) and a Si—H functional group containing organosilicon compound (b3) represented by formula (Iz). In addition, a process for preparing the catalyst component and the corresponding catalyst is described. The catalyst component and its catalyst have high catalytic activity, good hydrogen response, and good stereospecificity, the catalyst can release its activity more evenly, and the obtained polymer has significantly increased bulk density. The definitions of R1 to R10, n and z in the formulae (Ix), (ly) and (Iz) are as described in the specification.

Abstract: An object of the invention is to provide a solid polyaluminoxane composition suitably used as a cocatalyst and a catalyst carrier in combination with an olefin oligomerization or polymerization catalyst, without the use of solid inorganic carriers such as silica. The solid polyaluminoxane composition of the invention includes a polyalkylaluminoxane and a trialkylaluminum, and has a solubility in n-hexane at 25° C. of less than 0.50 mol % as measured by a specific method (i), a solubility in toluene at 25° C. of less than 1.0 mol % as measured by a specific method (ii), and a 13 mol % or more molar fraction of alkyl groups derived from the trialkylaluminum moieties relative to the total number of moles of alkyl groups derived from the polyalkylaluminoxane moieties and the alkyl groups derived from the trialkylaluminum moieties as measured with respect to tetrahydrofuran-d8 soluble components by a specific method (iii).

Abstract: A film-forming auxiliary suitable for use in a resin emulsion such as a fluororesin emulsion used as a raw material for a coating material or the like, the film-forming auxiliary containing emulsion particle, a polymer constituting the emulsion particle being obtained by emulsion polymerization of a monomer component in which the content ratio of a (meth)acrylate having a ring structure is 20-70% by mass, and the film-forming auxiliary being excellent in each of low-temperature film-forming property, warm water resistance, extensibility, weather resistance, vertical-surface coating property and warm water freezing stability.

Abstract: Provided is a production method for an olefin-based polymer, including polymerizing an olefin raw material using (A) a transition metal compound, (B) a boron compound capable of forming an ion pair with the component (A), (C) a specific organoaluminum compound, and (D) a specific aluminoxane in presence of at least one or more kinds of (N) a nonpolymerizable unsaturated hydrocarbon in the olefin raw material or a polymerization solvent.

Abstract: A process for preparing an ethylene copolymer in the presence of free-radical polymerization initiator at pressures from 150 MPa to 350 MPa and temperatures from 100° C. to 350° C., by copolymerizing ethylene and a comonomer having a C?C bond and optionally further comonomers, wherein the comonomer having the C?C bond is represented by formula wherein R1 is hydrogen or methyl; X1 is —CO—O— or —CO—NH—; R2 is —CH2—O—, —O—CO—, —Si(CH3)2—, —Si(CH3)2—O— or —CR5R6— wherein R5 and R6 are independently selected from hydrogen, methyl, ethyl and hydroxyl; n is an integer from 1 to 32 and R2 is same or different from each other when n is 2 to 32; and R3 is —C?C— and R4 is hydrogen, C1-C10 linear or branched alkyl, C1-C10 linear or branched hydroxyalkyl or phenyl, or the unit R3-R4 stands for wherein X2 is F, Cl, Br or I.

Abstract: Imidazoline functionalized oxidized fatty substance emulsifiers are made by obtaining a fatty substance composition; performing an oxidative oligomerization of the fatty substance composition to produce an oxidized fatty substance composition comprising from about 10 to about 75% by weight of oligomeric fatty acid components based on the total weight of fatty acid containing components in the composition; reacting the oxidized fatty substance composition with a polyamine comprising at least one ethylene diamine functional group with at least three hydrogens attached to the two nitrogens to form an aminoethylamido functionalized oxidized fatty substance composition; and forming an imidazoline functionalized oxidized fatty substance emulsifier from the aminoethylamido functionalized oxidized fatty substance composition. Such compositions are particularly useful in asphalt applications and corrosion inhibition.

Abstract: The present invention relates to a process for producing a propylene terpolymer comprising comonomer units derived from ethylene and from one alpha-olefin selected from the group of C4-C8 alpha-olefins and being characterized by a total content of comonomer units not less than 8% wt and a value of the ratio of ethylene to the C4-C8 alpha-olefins ranging from 0.1 to 0.8, said process being carried out in a gas-phase reactor comprising two interconnected polymerization zones. The present invention further relates to the propylene terpolymer obtained by said process particularly suitable to be used as films such as cast films, bi- or mono-oriented films and heat-sealable films having good optical properties and excellent sealing properties combined with good shrinkage properties and softness.

Abstract: The present invention relates to a super absorbent polymer and a preparation method thereof, the super absorbent polymer including: surface cross-linked polymer particles prepared by surface cross-linking particles of a base resin, the base resin polymerized from a monomer composition including water-soluble ethylene-based unsaturated monomers having at least partially neutralized acidic groups; and a water-soluble component, wherein the water-soluble component has a weight average molecular weight of 150,000 to 300,000 g/mol. The super absorbent polymer may have high centrifuge retention capacity and excellent permeability at the same time, while having low content of the water-soluble component.

Abstract: A copolymer comprising (A) 20-50% (w/w) of methyl methacrylate (MMA), (B) 40-80% (w/w) of one or more vinylaromatic(s) and, optionally, (C) 0-10% (w/w) of one or more aliphatic vinyl(s) can be used in a polymer composition for generating translucent final products.

Abstract: The present disclosure relates to an acrylic processing aid and a vinyl chloride resin composition including the same, and in particular, to a core-shell-structured acrylic processing aid preparing a core using a silicone-azo macroinitiator and preparing a shell using C12 to C18 alkyl methacrylate as a co-monomer, and a vinyl chloride resin composition including the same. The acrylic processing aid is used for sheet forming of the vinyl chloride resin, and facilitates manufacture of a high-quality vinyl chloride resin formed article having excellent transparency, adhesion resistance and heat stability, having no non-dispersed melt (fish-eye) production, and having significantly reduced air mark and flow mark occurrences.

Abstract: The present application provides the block copolymers and their application. The block copolymer has an excellent self assembling property and phase separation and various required functions can be freely applied thereto as necessary.

Abstract: A polymer has urethane or thiourethane units, which can be used, in particular, as an adhesion primer for the adhesive bonding of metal or glass to rubber. The polymer comprises base units comprising at least a sub-unit of formula X1CO—NH—, in which X1 respectively represents O or S, and additional units comprising at least a secondary alcohol function and a thioether function in the ? position relative to the alcohol function. The polymer can be used as an adhesion primer for the adhesive bonding of a substrate, for example glass or metal, to an unsaturated rubber, or as a corrosion-resistant protective coating for a metal substrate. A metal reinforcer, such as wire, cord, film or plate, can be coated with the polymer.

Abstract: A method for making joints in an electrical cable is disclosed. A first cable having polymeric insulation and a first bare conductor end and a second cable having polymeric insulation and a second bare conductor end are provided and joined create a conductor joint. A curable reaction mixture is applied over the conductor joint and cured to form a polymeric insulating sheath over the conductor joint and bonded to the polymeric insulation of each of the first and second cables. The reaction mixture includes a carbon-Michael acceptor compound, a carbon-Michael donor compound and a carbon-Michael reaction catalyst.

Abstract: A dual curable composition is provided, comprising a compound represented by formula (I): (acrylate)a-(A)-(silane)b??(I) in which a and b are identical or different and are each represented by an integer greater than or equal to 1; and wherein the dual curable composition is radiation curable and/or moisture curable. The moiety A comprises at least one of an aliphatic hydrocarbon, a cycloaliphatic hydrocarbon, an aryl moiety, an ether, an ester, an amide, a urethane, a urea, a hydroxyl group-containing organic moiety, an acrylic oligomer, an epoxy oligomer, a urethane oligomer, a polyester oligomer, or mixtures thereof, and the dual curable composition has a molecular weight greater than or equal to 300.

Abstract: The efficient production of poly(tetramethylene ether) diacetate [PTMEA] or other diesters, from tetrahydrofuran [THF] is obtained utilizing an acid-based catalyst that is based on a morphologically reconfigured and Bronsted acidity enhanced halloysite derived from a preparation method of using naturally occurring halloysites. More specifically, the method relates to morphological modification of the internal pore structure of halloysites via supercritical carbon dioxide treatment directly applied onto the raw halloysite minerals, that yields highly synergistic and reproducible results of elimination of inaccessible and detrimental extra-small pores. PTMEA is readily converted to poly(tetramethylene ether) glycol (PTMEG) by a transesterification reaction.

Abstract: Disclosed are processes and systems for removing water from a polyether polyol that employs a controlled temperature and pressure profile.

Abstract: The present invention relates to a composition containing a particulate solid, a polar or non-polar organic medium, and a polymer chain having at least one non-fused aromatic imide pendant group. The invention further provides compositions for coatings, inks, toners, plastic materials (such as thermoplastics), plasticisers, plastisols, crude grinding and flush.

Abstract: Amine-aldehyde resins are disclosed for removing a wide variety of solids and/or ionic species from the liquids in which they are suspended and/or dissolved. These resins are especially useful as froth flotation depressants, for example in the beneficiation of value materials (e.g., bitumen, coal, or kaolin clay) to remove impurities such as sand. The resins are also useful for treating aqueous liquid suspensions to remove solid particulates, as well as for removing metallic ions in the purification of water.

Abstract: Prepare a carbon molecular sieve membrane from a polyimide (e.g., a 6FDA/BPDA-DAM polyimide) that has a glass transition temperature of at least 400° C. and includes a bridged phenyl compound for separation of hydrogen and ethylene from one another whether present as a pure mixture of hydrogen and ethylene or as components of a cracked gas. Preparation comprises two sequential steps a) and b). In step a), place a membrane fabricated from defect-free fibers of the polyimide in contact with an oxygen-containing atmosphere under conditions of time and temperature sufficient to produce a pre-oxidized and pre-carbonized polymeric membrane that is insoluble in hot (110 C) n-methylpyrolidone and at least substantially free of substructure collapse.

Abstract: Polymers, monomers, chromophoric polymer dots and related methods are provided. Highly fluorescent chromophoric polymer dots with narrow-band emissions are provided. Methods for synthesizing the chromophoric polymers, preparation methods for forming the chromophoric polymer dots, and biological applications using the unique properties of narrow-band emissions are also provided.

Abstract: A method of preparing condensation cross-linked particles in an emulsion includes combining a first linear reactant having two unsaturated carbon-carbon moieties, a second linear reactant having two Si—H moieties, and a third reactant having at least one condensable reactive group and having up to two unsaturated carbon-carbon moieties or Si—H moieties with the proviso that the third reactant has at least one unsaturated carbon-carbon moiety or Si—H moiety. The first, second, and third reactants are combined in the presence of a hydrosilylation catalyst and a polar liquid to form an emulsion wherein the first, second, and third reactants react via a hydrosilylation reaction to form particles that have a linear backbone wherein the condensable reactive group is disposed thereon. The method also includes cross-linking the linear backbone via a condensation reaction to form the condensation cross-linked particles.

Abstract: Methods and systems are provided for improved liquefaction of a lignocellulosic biomass. The methods include reacting a lignocellulosic biomass slurry at mild conditions for a short period to produce a first reaction mixture having a reduced viscosity as compared to the lignocellulosic biomass slurry and that is substantially free of levulinic acid and hydroxymethylfurfural. The methods further include separating the first reaction mixture into a solid fraction and a liquid fraction, the solid fraction having a majority of lignin from the lignocellulosic biomass slurry and the liquid fraction having a majority of hemicellulose and greater than about 30% by weight of cellulose from the lignocellulosic biomass slurry. The method advantageously prevents or eliminates the formation of tar and/or char.

Abstract: Nanoemulsions are prepared by: a) solubilizing a silicone resin in an organic solvent system to yield a silicone resin solution concentration of 80% or less, wherein the organic solvent system comprises diethyleneglycol monobutyl ether and at least one additional solvent; b) mixing the silicone resin solution from a) with an aminosiloxane polymer to obtain an aminosiloxane polymer: silicone resin mixture; c) allowing the resin mixture to age for at least about 6 hours at ambient temperature; d) adding the resin mixture to a vessel; e) optionally adding with agitation an additional organic solvent to the resin mixture; f) mixing until homogenous; g) adding a protonating agent; h) adding an aqueous carrier in an amount to produce a desired concentration of emulsion.